These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Detection of SARS-CoV-2 antibodies in febrile patients from an endemic region of dengue and chikungunya in Peru. Tarazona-Castro Y, Troyes-Rivera L, Martins-Luna J, Cabellos-Altamirano F, Aguilar-Luis MA, Carrillo-Ng H, Del Valle LJ, Kym S, Miranda-Maravi S, Silva-Caso W, Levy-Blitchtein S, Del Valle-Mendoza J. PLoS One; 2022 Dec 21; 17(4):e0265820. PubMed ID: 35395015 [Abstract] [Full Text] [Related]
3. Cross-Neutralizing Anti-Chikungunya and Anti-Dengue 2 IgG Antibodies from Patients and BALB/c Mice against Dengue and Chikungunya Viruses. Posadas-Mondragón A, Santiago-Cruz JA, Pérez-Juárez A, Herrera-González NE, Sosa-Delgado SM, Wong-Arámbula CE, Rodríguez-Maldonado AP, Vázquez-Pichardo M, Duran-Ayala D, Aguilar-Faisal JL. Viruses; 2024 Jul 08; 16(7):. PubMed ID: 39066260 [Abstract] [Full Text] [Related]
4. Evaluation of an immunochromatography rapid diagnosis kit for detection of chikungunya virus antigen in India, a dengue-endemic country. Jain J, Okabayashi T, Kaur N, Nakayama E, Shioda T, Gaind R, Kurosu T, Sunil S. Virol J; 2018 May 11; 15(1):84. PubMed ID: 29751761 [Abstract] [Full Text] [Related]
5. Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis. Cheng YL, Chao CH, Lai YC, Hsieh KH, Wang JR, Wan SW, Huang HJ, Chuang YC, Chuang WJ, Yeh TM. Front Immunol; 2022 May 11; 13():941923. PubMed ID: 36045680 [Abstract] [Full Text] [Related]
6. Evaluation of Serologic Cross-Reactivity Between Dengue Virus and SARS-CoV-2 in Patients with Acute Febrile Illness - United States and Puerto Rico, April 2020-March 2021. Munoz-Jordan J, Cardona J, Beltrán M, Colón C, Schiffer J, Stewart-Clark E, Zellner B, Semenova V, Li Y, Jia LT, Maniatis P, Pawloski L, Adams L, Paz-Bailey G, Rivera-Amill V, Medina F. MMWR Morb Mortal Wkly Rep; 2022 Mar 11; 71(10):375-377. PubMed ID: 35271558 [Abstract] [Full Text] [Related]
7. Low Risk of Serological Cross-Reactivity between the Dengue Virus and SARS-CoV-2-IgG Antibodies Using Advanced Detection Assays. Shurrab FM, Al-Sadeq DW, Amanullah FH, Al-Absi ES, Qotba H, Yassine HM, Abu-Raddad LJ, Nasrallah GK. Intervirology; 2022 Mar 11; 65(4):224-229. PubMed ID: 35134813 [Abstract] [Full Text] [Related]
13. Molecular characterization of dengue and chikungunya virus strains circulating in New Delhi, India. Afreen N, Deeba F, Khan WH, Haider SH, Kazim SN, Ishrat R, Naqvi IH, Shareef MY, Broor S, Ahmed A, Parveen S. Microbiol Immunol; 2014 Dec 11; 58(12):688-96. PubMed ID: 25346397 [Abstract] [Full Text] [Related]
15. Covert cases of Severe Acute Respiratory Syndrome Coronavirus 2: An obscure but present danger in regions endemic for Dengue and Chikungunya viruses. Stringari LL, de Souza MN, de Medeiros Junior NF, Goulart JP, Giuberti C, Dietze R, Ribeiro-Rodrigues R. PLoS One; 2021 Dec 11; 16(1):e0244937. PubMed ID: 33406122 [Abstract] [Full Text] [Related]